What is the 13F Pro Quality Score for MEDP?

13F Pro ranks Medpace Holdings, Inc. (MEDP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MEDP's current score at https://13fpro.ai/research/MEDP (free sign-up required for the full ranking).

Where does 13F Pro source MEDP data?

All Medpace Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Medpace Holdings, Inc. files with the SEC under CIK 1668397. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MEDP in?

Medpace Holdings, Inc. (MEDP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MEDP research updated on 13F Pro?

MEDP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Medpace Holdings, Inc.(MEDP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1668397 MEDP stock profile & AI dashboard →

13F Pro Quality Score

77.4/100

Rank #86 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

75.4/100

Profitability

80.5/100

Balance Sheet

97.5/100

Earnings Quality

68.2/100

Free Cash Flow

82.6/100

Institutional Flow

66.8/100

Revenue Scale

66.5/100

Dilution Risk

49.0/100

MEDP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Medpace Holdings, Inc. (MEDP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MEDP at 77.4/100 on a 32-signal composite quality model, placing it at rank #86 of 2,879 stocks — the top 5% of the AI-ranked universe. MEDP scores in the top quartile across balance sheet strength (97.5), free cash flow (82.6), profitability (80.5). Shareholder dilution risk is elevated at 49.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Medpace Holdings, Inc. reports quarterly revenue of $706.6M, net income of $123.9M, an operating margin of 20.0%. Top institutional holders of MEDP by reported 13-F value include BlackRock,, AQR CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. MEDP trades on the Nasdaq exchange and files with the SEC under CIK 1668397. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MEDP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medpace Holdings, Inc. directly from SEC EDGAR. Medpace Holdings, Inc.'s 13F Pro composite quality score has ranged between 8 and 82 since 2021, currently 77.4 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Medpace Holdings, Inc.

Quirks, history, and lore behind MEDP — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mid-cap · listed on Nasdaq · headquartered in Cincinnati, Ohio.
2
The Numbers
Annual revenue in the range of roughly $2 billion, with operating margins that make most contract-service peers jealous — consistently above 20%.
3
The History
Founded in the 1990s in Cincinnati, it grew by staying laser-focused on one thing: running clinical trials for drug and device makers rather than chasing flashier healthcare businesses.
4
The Secret
It operates as a contract research organization (CRO) — meaning pharmaceutical and biotech companies outsource their Phase I–IV drug development studies entirely to its teams.
5
The Lore
Unlike its giant CRO rivals, this company is famously owner-operated, with management holding a large stake and a reputation for running an unusually lean, no-frills culture that Wall Street has rewarded handsomely.
6
The Giveaway
A Cincinnati-based CRO with the ticker that sounds like a doctor's order — MEDP — and a founder-led identity that makes it the boutique darling of the clinical research outsourcing world.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$706.6M

Net Income

Q1 2026

$123.9M

Free Cash Flow

Q1 2026

$145.0M

Operating Margin

Q1 2026

20.0%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+20.0% YoY

$2.53BFY 2025

FY22 $1.46BFY23 $1.89BFY24 $2.11BFY25 $2.53B

Net Income

+11.6% YoY

$451.1MFY 2025

FY22 $245.4MFY23 $282.8MFY24 $404.4MFY25 $451.1M

Operating Income

+19.7% YoY

$534.9MFY 2025

FY22 $278.7MFY23 $336.8MFY24 $446.9MFY25 $534.9M

EPS (Diluted)

+21.0% YoY

$15.28FY 2025

FY22 $7.28FY23 $8.88FY24 $12.63FY25 $15.28

Total Assets

-6.0% YoY

$1.98BFY 2025

FY22 $1.35BFY23 $1.66BFY24 $2.10BFY25 $1.98B

Total Debt

—FY 2025

FY22 $50.0MFY23 $0.00FY24 —FY25 —

Op. Cash Flow

+17.1% YoY

$713.2MFY 2025

FY22 $388.1MFY23 $433.4MFY24 $608.8MFY25 $713.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.53B +20.0%	$2.11B +11.8%	$1.89B +29.2%	$1.46B +27.8%	$1.14B +23.4%	$925.9M
Net Income	$451.1M +11.6%	$404.4M +43.0%	$282.8M +15.3%	$245.4M +34.9%	$181.8M +25.1%	$145.4M
Operating Income	$534.9M +19.7%	$446.9M +32.7%	$336.8M +20.9%	$278.7M +40.3%	$198.6M +18.9%	$167.0M
EPS (Diluted)	$15.28 +21.0%	$12.63 +42.2%	$8.88 +22.0%	$7.28 +51.4%	$4.81 +25.3%	$3.84
Total Assets	$1.98B -6.0%	$2.10B +26.8%	$1.66B +22.5%	$1.35B -18.5%	$1.66B +19.4%	$1.39B
Total Debt	—	—	$0.00 -100.0%	$50.0M	$0.00	—
Operating Cash Flow	$713.2M +17.1%	$608.8M +40.5%	$433.4M +11.7%	$388.1M +47.4%	$263.3M +1.8%	$258.7M

Get alerted when MEDP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Medpace Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MEDP

BlackRock, Inc.
$1.2B2,470,440 sh
AQR CAPITAL MANAGEMENT LLC
$633.6M1,353,837 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$538.6M1,121,689 sh
VANGUARD CAPITAL MANAGEMENT LLC
$485.5M1,011,071 sh
WASATCH ADVISORS LP
$371.6M773,931 sh
GEODE CAPITAL MANAGEMENT, LLC
$357.8M745,106 sh
STATE STREET CORP
$327.6M682,229 sh
Invesco Ltd.
$277.3M577,574 sh
RENAISSANCE TECHNOLOGIES LLC
$242.3M504,668 sh
BAILLIE GIFFORD & CO
$241.6M503,191 sh

Fund	Value	Shares
BlackRock, Inc.	$1.2B	2,470,440
AQR CAPITAL MANAGEMENT LLC	$633.6M	1,353,837
VANGUARD PORTFOLIO MANAGEMENT LLC	$538.6M	1,121,689
VANGUARD CAPITAL MANAGEMENT LLC	$485.5M	1,011,071
WASATCH ADVISORS LP	$371.6M	773,931
GEODE CAPITAL MANAGEMENT, LLC	$357.8M	745,106
STATE STREET CORP	$327.6M	682,229
Invesco Ltd.	$277.3M	577,574
RENAISSANCE TECHNOLOGIES LLC	$242.3M	504,668
BAILLIE GIFFORD & CO	$241.6M	503,191

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MEDP on your watchlist

Track score changes the day Medpace Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MEDP a good stock to buy?

13F Pro's AI-powered analysis of Medpace Holdings, Inc. (MEDP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MEDP are available on the MEDP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MEDP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MEDP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Medpace Holdings, Inc.'s investment landscape.